Last reviewed · How we verify
nefopam, ketoprofen, paracetamol
Nefopam is a non-opioid analgesic that acts as an NMDA receptor antagonist, inhibiting the release of pain-producing neurotransmitters.
Nefopam is a non-opioid analgesic that acts as an NMDA receptor antagonist, inhibiting the release of pain-producing neurotransmitters. Used for Moderate to severe pain, Migraine prophylaxis.
At a glance
| Generic name | nefopam, ketoprofen, paracetamol |
|---|---|
| Sponsor | American University of Beirut Medical Center |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
Nefopam's mechanism of action is thought to involve the inhibition of NMDA receptors, which are involved in the transmission of pain signals in the brain. This leads to a reduction in the release of pain-producing neurotransmitters, resulting in analgesia. Additionally, nefopam may also have a weak inhibitory effect on the release of serotonin and norepinephrine, which can contribute to its analgesic effects.
Approved indications
- Moderate to severe pain
- Migraine prophylaxis
Common side effects
- Dizziness
- Nausea
- Headache
- Somnolence
Key clinical trials
- Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes (NA)
- Non-steroidal Anti-inflammatory in Cardiac Surgery (PHASE3)
- Chest Wall Block After Sternotomy: Randomized Controlled Trial in Cardiac Surgery: (PABLOS Study) (PHASE3)
- Non-steroidal Anti-inflammatory Drugs in Pleurodesis (PHASE2)
- Nonopioid Analgesics and Cholecystectomy (PHASE3)
- Effect of Bilateral Transversus Thoracis Muscle Plane Block in Patients Undergoing Coronary Artery Bypass Graft Surgery.
- Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
- Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: